Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Hib Vaccine Recommendations

One of the Recommended Vaccines by Disease


Below are summaries of recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP). For the full text of the recommendations, see Haemophilus influenzae type b (Hib) ACIP Vaccine Recommendations.


Routine Vaccination of Infants and Children

CDC recommends routine administration of a conjugate Hib vaccine series beginning at age 2 months:

  • Infants 2 through 6 months of age should receive a 3-dose series of Hib PRP-T as ActHib®, Hiberix®, or Pentacel® or a 2-dose series of Hib PRP-OMP as PedvaxHib® (Table 1).
  • The first dose can be administered as early as age 6 weeks.
  • A booster dose (which will be dose 3 or 4 depending on vaccine type used in the primary series) of any licensed conjugate Hib vaccine is recommended at age 12 through 15 months and at least 8 weeks after the most recent Hib vaccination.


Catch-up Guidance for Children 4 Months through 18 Years

The following “job-aids” provide catch-up guidance for Hib vaccination for children 4 months through 18 years of age, including detailed scenarios by age group and previous doses of vaccine received. These materials should assist healthcare professionals in interpreting Figure 2 of the Childhood/Adolescent Immunization catch-up schedule.


Contraindications and Precautions

Hib vaccines should not be administered to:

  • A person who has ever had a severe allergic reaction (e.g., anaphylaxis) after a previous dose
  • A person who has a severe allergy to any vaccine component
  • A person younger than 6 weeks

Hib vaccines may be administered, if the provider and parent deems the benefits of vaccination to outweigh the risks, to:

  • A person who has a moderate or severe acute illness with or without fever

 Top of Page